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Brexpiprazole, a novel atypical antipsychotic drug, is currently being tested in clinical trials for
treatment of psychiatric disorders, such as schizophrenia and major depressive disorder. The drug is
known to act through a combination of partial agonistic activity at 5-hydroxytryptamine (5-HT)1A,
and dopamine D2 receptors, and antagonistic activity at 5-HT2A receptors. Accumulating evidence
suggests that antipsychotic drugs act by promoting neurite outgrowth. In this study, we examined
whether brexpiprazole affected neurite outgrowth in cell culture. We found that brexpiprazole
signiﬁcantly potentiated nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells, in a
concentration dependent manner. The selective 5-HT1A receptor antagonist, WAY-100,635, was able
to block the effects of brexpiprazole on neurite outgrowth, unlike the selective dopamine
D2 receptor antagonist, raclopride. Furthermore, the selective 5-HT2A receptor antagonist
M100907, but not DOI (5-HT2A receptor agonist), signiﬁcantly potentiated NGF-induced neurite
outgrowth. Moreover, xestospongin C and 2-aminoethoxydiphenyl borate (2-APB), both speciﬁc
inhibitors of inositol 1,4,5-triphosphate (IP3) receptors, signiﬁcantly blocked the effects of
brexpiprazole. These ﬁndings suggest that brexpiprazole-induced neurite outgrowth is mediated
through 5-HT1A and 5-HT2A receptors, and subsequent Ca
2+ signaling via IP3 receptors.
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T. Ishima et al.5061. Introduction
Brexpiprazole, an atypical antipsychotic drug, is currently
being tested in clinical trials evaluating the treatment of
schizophrenia, agitation associated with Alzheimer's disease
and as an adjunct treatment of post-traumatic stress
disorder (PTSD) and major depressive disorder (Citrome,
2013). Brexpiprazole is a potent partial agonist at human 5-
hydroxytryptamine (5-HT) 5-HT1A (Ki=0.12 nM) and dopa-
mine D2L (Ki=0.3 nM) receptors, and an antagonist at 5-
HT2A receptors (Ki=0.47 nM) (Maeda et al., 2014a). It also
shows potent antagonist activity at human noradrenergic
α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM) (Maeda
et al., 2014a). Furthermore, this drug displays moderate
afﬁnity for human D3, 5-HT2B and 5-HT7 receptors, as well as
α1A, and α1D adrenergic receptors (Maeda et al., 2014a).
Strong evidence suggests that at the cellular level,
neuronal plasticity demonstrated by neurite outgrowth
and neuroprotection, underlie the therapeutic effects of
atypical antipsychotic drugs (Lu and Dwyer, 2005; Williams
and Dwyer, 2009; Lieberman et al., 2008; Molteni et al.,
2009). PC12 cells, a cell line derived from a pheochromo-
cytoma of the rat adrenal medulla, constitute a recognized
model system for nerve growth factor (NGF)-induced neur-
ite outgrowth (Nishimura et al., 2008; Ishima et al., 2008,
2012; Minase et al., 2010; Hashimoto and Ishima, 2010,
2011; Itoh et al., 2011; Ishima and Hashimoto, 2012).
Recently, we reported that aripiprazole, an antipsychotic
drug, could potentiate NGF-induced neurite outgrowth in
PC12 cells, most likely through interaction with 5-HT1A
receptors (Ishima et al., 2012).
The primary purpose of this study was to determine whether
brexpiprazole could promote NGF-induced neurite outgrowth in
PC12 cells. Next, we examined the role of 5-HT1A, 5-HT2A and
dopamine D2 receptors in the mechanistic action of brexpipra-
zole. We also analyzed the role of intracellular Ca2+ and the
endoplasmic reticulum (ER) protein, inositol 1,4,5-triphosphate
(IP3) receptor, on brexpiprazole mediated potentiation of NGF-
induced neurite outgrowth. This was deemed relevant since
Ca2+ signaling via IP3 receptors is crucial to NGF-induced
neurite outgrowth (Nishimura et al., 2008; Ishima et al.,
2008, 2012; Minase et al., 2010; Hashimoto and Ishima, 2010,
2011; Itoh et al., 2011; Ishima and Hashimoto, 2012). Finally,
we examined whether brexpiprazole increased the heat shock
protein, Hsp90α, since regulation of Hsp90α by aripiprazole
appeared to potentiate the process of neurite outgrowth
(Ishima et al., 2012).2. Experimental procedures
2.1. Drugs
Drugs were obtained from the following sources: brexpiprazole and
aripiprazole (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan); xestos-
pongin C and M100,907 (volinanserin) (Wako Pure Chemicals Inc., Tokyo,
Japan); WAY-100,635, ﬂuoxetine hydrochloride, paroxetine hydrocloride
and 1-(2,5-dimethoxy-4-iodophenyl)-2-aminpprapane (DOI) hydrochlor-
ide (Sigma-Aldrich, St Louis, MO, USA); nerve growth factor (NGF)
(Alomone Labs Ltd., Jerusalem, Israel); and raclopride (Tocris
Bioscience, Bristol, UK); 2-aminoethoxydiphenyl borate (2-APB) (Calbio-
chem-Novabiochem, San Diego, CA, USA). All other drugs were
purchased from commercial sources. All drugs (10 mM) were dissolvedin dimethyl sulfoxide (DMSO), and then were diluted in the medium.
The ﬁnal concentration of DMSO did not affect the cell viability in
PC12 cells.
2.2. Cell culture and quantiﬁcation of neurite
outgrowth
PC12 cells (RIKEN Cell Bank, Tsukuba, Japan) were cultured at 37 1C,
5% CO2 in Dulbecco's modiﬁed Eagle's medium (DMEM), supplemented
with 5% heat-inactivated fetal bovine serum (FBS), 10% heat-
inactivated horse serum, and 1% penicillin–streptomycin. Medium was
changed two to three times a week. PC12 cells were plated onto 24-
well tissue culture plates coated with poly-D-lysine/laminin. Cells were
plated at relatively low density (0.25 104 cells/cm2) in DMEM medium
containing 0.5% FBS, 1% penicillin–streptomycin. Medium containing a
minimal level of serum (0.5% FBS) was used as previously reported
(Nishimura et al., 2008; Ishima et al., 2008, 2012; Minase et al., 2010;
Hashimoto and Ishima, 2010, 2011; Itoh et al., 2011; Ishima and
Hashimoto, 2012). Previously, we examined the optimal concentration of
NGF needed to induce neurite outgrowth in PC12 cells, and found that
NGF (2.5, 5, 10, 20, 40 ng/ml) increased the number of cells with
neurite outgrowth in a concentration-dependent manner (Nishimura
et al., 2008). In this study, 2.5 ng/ml of NGF was used to study the
potentiating effects of brexpiprazole on neurite outgrowth. Twenty-four
hours after plating, the medium was replaced with DMEM medium
containing 0.5% FBS and 1% penicillin–streptomycin with NGF (2.5 ng/
ml), with or without brexpiprazole (0.001, 0.01, 0.1 or 1.0 μM), WAY-
100,635 (5-HT1A receptor antagonist; 10 μM), raclopride (dopamine D2
receptor antagonist; 10 μM), DOI (5-HT2A receptor agonist; 0.1, 1.0 or
10 μM), M100,907 (5-HT2A receptor antagonist; 0.1, 1.0 or 10 μM),
xestospongin C (IP3 receptor antagonist; 1.0 μM), 2-APB (IP3 receptor
antagonist; 100 μM), ﬂuoxetine (5-HT transporter inhibitor: 1.0 μM), or
paroxetine (5-HT transporter inhibitor: 1.0 μM).
Four days after incubation with NGF (2.5 ng/ml) with or without
speciﬁed drugs, morphometric analysis was performed on digitized
images of live cells taken under phase-contrast illumination, with an
inverted microscope linked to a camera. Images of three ﬁelds per well
were taken, with an average of 100 cells per ﬁeld. Differentiated cells
were counted by visual examination of the ﬁeld; only cells that had at
least one neurite with a length equal to the cell body diameter were
counted, and were then expressed as a percentage of the total cells in
the ﬁeld. Counting was performed in a blinded manner.
2.3. Western blot analysis of HSP90α
Western blot analysis was performed as reported previously (Ishima
et al., 2012). PC12 cells were washed with PBS and lysed in Laemmli
lysis buffer. Aliquots (30 μg) of protein were measured using the DC
protein assay kit (Bio-Rad, Hercules, CA, USA) and incubated for 5 min
at 95 1C, with an equal volume of 125 mM Tris/HCl, pH 6.8, 20%
glycerol, 0.1% bromophenol blue, 10% β-mercaptoethanol, 4% SDS, and
subjected to SDS-PAGE, using 7.5% mini-gels (Mini Protean II; Bio-Rad,
Hercules, CA, USA). Proteins were transferred onto PVDF membranes
using a Trans Blot Mini Cell (Bio-Rad, Hercules, CA, USA). For
immunodetection, the blots were blocked for 1 h in TBST (50 mM
Tris/HCl, pH 7.8, 0.13 M NaCl, 0.1% Tween 20) containing 5% nonfat dry
milk at RT, followed by incubation with rabbit anti-HSP90α antibody
(1:2000, ab2928, Abcam, Cambridge, UK), overnight at 4 1C, in 5%
TBST blocking buffer. The blots were washed ﬁve times with TBST.
Incubation with the secondary antibody (GE Healthcare Bioscience, UK)
was performed for 1 h, at RT. After extensive washing, immunoreac-
tivity was detected by ECL Prime Western Blotting Detection reagent
(GE Healthcare Bioscience, UK). Images were captured and immunor-
eactive bands were quantiﬁed using a Fuji LAS3000-mini imaging
system (Fujiﬁlm, Tokyo, Japan) with Multi Gauge software (Ver.3.0;
Fujiﬁlm, Tokyo, Japan). β-actin immunoreactivity was used to monitor
equal sample loading.
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Data are expressed as means7standard error of the mean (S.E.M.).
Statistical analysis was performed using one-way analysis of var-
iance (ANOVA) or two-way ANOVA. When appropriate, post-hoc
comparisons were performed using the Bonferroni/Dunn test. P
values less than 0.05 were considered statistically signiﬁcant.
3. Results
3.1. Brexpiprazole potentiated NGF-induced
neurite outgrowth in PC12 cells
As shown in Figure 1A, brexpiprazole (1.0 μM) increased the
number of cells with neurites in PC12 cells. One-way ANOVA
analysis revealed that the number of cells with neurites of six
groups was signiﬁcantly different (F (5, 66)=16.95, Po0.001).
Treatment with brexpiprazole (0.001, 0.01, 0.1 or 1.0 μM) in
conjunction with NGF (2.5 ng/ml) increased the number of
cells with neurites, in a concentration-dependent manner
(Figure 1B). Effect of brexpiprazole (1.0 μM) on neurite out-
growth was similar to that of aripiprazole (1.0 μM) (Figure 1B).
3.2. Role of 5-HT1A receptors in brexpiprazole
mediated potentiation of NGF-induced neurite
outgrowth
In order to examine the role of 5-HT1A receptor in brexpipra-
zole's action on neurite outgrowth, we examined the effects of
selective 5-HT1A receptor antagonist WAY-100,635. Two-way
ANOVA analysis revealed a signiﬁcant interaction [brexpiprazo-
leWAY-100,635: F (1, 20)=11.31, P=0.003]. Treatment with
WAY-100,635 (10 μM) signiﬁcantly blocked the potentiation of
NGF-induced neurite outgrowth by brexpiprazole (1.0 μM)
(Figure 2A). In contrast, two-way ANOVA analysis revealed no
differences in interaction [brexpiprazole raclopride: F (1, 20)
=1.260, P=0.275]. Treatment with raclopride (10 μM) failed to
potentiate neurite outgrowth in the presence of NGF and
brexpiprazole (Figure 2B). Furthermore, WAY-100,635 (10 μM)
alone or raclopride (10 μM) alone did not alter NGF-induced
neurite outgrowth in PC12 cells (Figure 2A and B). Collectively,
these ﬁndings suggest that activation at 5-HT1A receptors, as
opposed to dopamine D2 receptors, may play a role in the
mechanisms of brexpiprazole-induced neurite outgrowth.
3.3. Role of 5-HT2A receptors in brexpiprazole
mediated potentiation of NGF-induced neurite
outgrowth
In order to examine the role of 5-HT2A receptor in brexpi-
prazole's action on neurite outgrowth, we examined the
effects of selective 5-HT2A receptor agonist DOI and 5-HT2A
receptor antagonist M100,907. One-way ANOVA analysis of
DOI's data revealed no difference [F (3, 44)=1.253,
P=0.302](Figure 3A). In contrast, one-way ANOVA analysis
of M100,907's data revealed a signiﬁcant effect [F (3, 68)
=14.73, Po0.001]. Treatment with M100,907 (0.1, 1.0, or
10 μM) potentiated NGF-induced neurite outgrowth, in a
concentration dependent manner (Figure 3B). Collectively,
these ﬁndings suggest that antagonism at 5-HT2A receptorsmay play a role in the mechanisms of brexpiprazole-induced
neurite outgrowth.3.4. The potentiating effect of brexpiprazole on
the effects of ﬂuoxetine and paroxetine on NGF-
induced neurite outgrowth
We examined whether brexpiprazole could potentiate the
effect of the antidepressants (ﬂuoxetine and paroxetine) on
neurite outgrowth. One-way ANOVA analysis revealed a sig-
niﬁcant effect [F (5, 66)=11.24, Po0.001]. Post-hoc analysis
showed that ﬂuoxetine (1.0 μM), but not paroxetine (1.0 μM),
signiﬁcantly potentiated neurite outgrowth, consistent with a
previous report (Nishimura et al., 2008). Addition of brexpipra-
zole (1.0 μM) signiﬁcantly could potentiate the effects of
ﬂuoxetine, but not paroxetine, on neurite outgrowth (Figure 4).3.5. Role of IP3 receptors on the potentiation of
NGF-induced neurite outgrowth by brexpiprazole
The IP3 receptors on the ERs are part of the signaling
pathway that promotes NGF-induced neurite outgrowth in
PC12 cells (Nishimura et al., 2008; Ishima et al., 2008, 2012;
Minase et al., 2010; Hashimoto and Ishima, 2010, 2011; Itoh
et al., 2011; Ishima and Hashimoto, 2012). To investigate
the role of IP3 receptors in brexpiprazole's action on neurite
outgrowth, we examined the effects of xestospongin C (a
selective, reversible and membrane-permeable inhibitor of
IP3 receptors) (Gafni et al., 1997) and 2-APB (Maruyama
et al., 1997; Ma et al., 2000) on the culture system. Two-
way ANOVA analysis revealed signiﬁcant interactions [brex-
piprazole xestospongin C: F (1, 20)=12.63, P=0.002,
brexpiprazole 2-APB: F (1, 20)=24.48, Po0.001]. Treat-
ment of xestospongin C (1.0 μM) or 2-APB (100 μM) with
brexpiprazole (1.0 μM) signiﬁcantly blocked the potentia-
tion of NGF-induced neurite outgrowth (Figure. 5A and B).
Neither xestospongin C (1.0 μM) nor 2-APB (100 μM) in the
absence of brexpiprazole promoted NGF-induced neurite
outgrowth in PC12 cells (Figure. 5A and B).3.6. Role of Hsp90α in the potentiation of NGF-
induced neurite outgrowth by brexpiprazole
Using a proteomics technique, we recently identiﬁed the
heat shock protein Hsp90α as being differentially expressed
between control PC12 cells treated with NGF (2.5 ng/ml)
and those treated with NGF (2.5 ng/ml) and aripiprazole
(1.0 μM)(Ishima et al., 2012). Previously, we reported that
increased expression of Hsp90α by aripiprazole was involved
in the potentiation of NGF-induced neurite outgrowth in
PC12 cells (Ishima et al., 2012).
To interrogate the proposed link between brexpiprazole
treatment and elevated Hsp90α production on NGF-induced
neurite outgrowth, we performed Western blot analysis of
Hsp90α. Similar to aripiprazole (1.0 μM), brexpiprazole
(1.0 μM) signiﬁcantly increased Hsp90α protein in PC12 cells
(Figure 6).
Figure 1 Brexpiprazole potentiated NGF-induced neurite outgrowth in PC12 cells. (A) Representative photomicrographs in PC12 cells.
Control: NGF (2.5 ng/ml) alone, Brexpiprazole: NGF (2.5 ng/ml)+brexpiprazole (1.0 μM). Bar=50 μm (B) Effects of brexpiprazole and
aripiprazole on NGF-induced neurite outgrowth in PC12 cells. Brexpiprazole (0.001, 0.01, 0.1, or 1.0 μM) and aripiprazole (1.0 μM)
potentiated NGF-induced neurite outgrowth in PC12 cells, in a concentration-dependent manner. nnPo0.01, nnnPo0.001 as compared with
Control group. Data show the mean7SEM (n=12).
Figure 2 Role of 5-HT1A receptor in the mechanisms of brexpiprazole's potentiation of neurite outgrowth. (A) The selective 5-HT1A
receptor antagonist, WAY-100,635 (10 μM), blocked the effects of brexpiprazole. Data show the mean7SEM (n=6). (B) The dopamine
D2 receptor antagonist raclopride (10 μM) had no effect of brexpiprazole in NGF-induced neurite outgrowth. **Po0.01, ***Po0.001
as compared with NGF (2.5 ng/ml)+brexpiprazole (1.0 μM) group. The data show the mean7SEM (n=6).
T. Ishima et al.5084. Discussion
Our study found that brexpiprazole, a novel serotonin–
dopamine activity modulator, potentiated NGF-induced neu-
rite outgrowth in PC12 cells, through 5-HT1A receptors and
5-HT2A receptors, and subsequent Ca
2+ signaling via IP3receptors on the ER. Brexpiprazole is currently undergoing
testing in clinical trials as a therapy for neuropsychiatric
disorders. It is thought to act by partial agonism at 5-HT1A,
and dopamine D2 receptors, and antagonism at 5-HT2A
receptors. Brexpiprazole potentiated NGF-induced neurite
outgrowth in PC12 cells, and this effect was similar to
Figure 3 Role of 5-HT2A receptor in the mechanisms of
brexpiprazole's potentiation of neurite outgrowth. (A) The
selective 5-HT2A receptor agonist DOI (0.1, 1.0, or 10 μM) did
not effect NGF-induced neurite outgrowth. Data show the
mean7SEM (n=12). (B) The selective 5-HT2A receptor antago-
nist M100,907 (0.1, 1.0, or 10 μM) potentiated NGF-induced
neurite outgrowth. *Po0.05, ***Po0.001 as compared with
NGF (2.5 ng/ml) alone group. The data show the mean7SEM
(n=18).
Figure 4 Effect of brexpiprazole on the effects of NGF-induced
neurite outgrowth by ﬂuoxetine (1.0 μM) or paroxetine (1.0 μM).
Addition of brexpiprazole (1.0 μM) potentiated the effects of
ﬂuoxetine, but not paroxetine, on NGF-induced neurite out-
growth. Data show the mean7SEM (n=12). *Po0.05,
***Po0.001 as compared with control group. +Po0.05 as
comparted with ﬂuoxetine group N.S.: Not signiﬁcant.
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be partially blocked by the selective 5-HT1A receptor
antagonist WAY-100,635, but not the dopamine D2 receptor
antagonist raclopride. Previously, we reported that the
selective 5-HT1A receptor agonist, 8-OH-DPAT also poten-
tiated NGF-induced neurite outgrowth in PC12 cells,
although to a lesser degree than aripiprazole (Ishima
et al., 2012). In this study, we found that the selective
5-HT2A receptor antagonist M100,907 could potentiate NGF-
induced neurite outgrowth in PC12 cells, suggesting that
5-HT2A receptor antagonism also may play a role in the
mechanisms of action of brexpiprazole. Thus, it would
appear that activation of 5-HT1A receptors as well as
blockage at 5-HT2A receptors is an integral part of the
mechanisms that drive brexpiprazole enhancement of NGF-
induced neurite outgrowth.
Previously, we reported that ﬂuoxetine, but not paroxetine,
could potentiate NGF-induced neurite outgrowth in PC12 cells,
and that the sigma-1 receptor antagonist NE-100 signiﬁcantly
antagonized the effect of ﬂuoxetine (Nishimura et al., 2008).
The study suggests that sigma-1 receptor agonism, but not 5-
HT transporter inhibition, plays a role in the mechanisms of
action of ﬂuoxetine on neurite outgrowth (Nishimura et al.,
2008; Hashimoto, 2009, 2013). In this study, we found that
ﬂuoxetine, but not paroxetine, could potentiate NGF-induced
neurite outgrowth, consistent with a previous report (Nishi-
mura et al., 2008). Interestingly, we found that brexpiprazole
signiﬁcantly could potentiate the effects of ﬂuoxetine (or
paroxetine) on neurite outgrowth. Since brexpiprazole has
been used as add-on therapy of the current antidepressant
therapy, the potentiating effect of brexpiprazole on neurite
outgrowth is of great interest.
Very recently, Maeda et al. (2014b) reported that brexpi-
prazole reversed cognitive impairment in rats after sub-
chronic treatment with the N-methyl-D-aspartate (NMDA)
receptor antagonist phencyclidine (PCP), and that this effect
was antagonized by co-treatment with WAY-100,635, a 5-HT1A
receptor antagonist. Subsequently, we found that brexpipra-
zole ameliorated cognitive deﬁcits in mice after repeated
dosing with PCP, and that this effect was antagonized by co-
treatment with WAY-100,635 (Yoshimi et al., 2014). Very
recently, we reported that brexpiprazole improved social
recognition deﬁcits in mice after administration of the NMDA
receptor antagonist dizocilpine, and that this effect was
antagonized by WAY-100,635 (Yoshimi et al., 2015). These
ﬁndings suggest a role for 5-HT1A receptors in the mechan-
isms of action of brexpiprazole for PCP (or dizocilpine)-
induced cognitive impairment (Maeda et al., 2014b; Yoshimi
et al., 2014, 2015). Given that altered 5-HT1A receptor
function is implicated in schizophrenia related cognitive
impairment (Sumiyoshi et al., 2007; Meltzer and Sumiyoshi,
2008; Hagiwara et al., 2008; Yoshida et al., 2012), activation
of this receptor by brexpiprazole may confer a beneﬁcial
effect in psychiatric diseases, where patients suffer cognitive
deﬁcits. So far these data suggest that the therapeutic
actions of brexpiprazole are in part mediated by activation
of 5-HT1A receptors.
Inositol 1,4,5-triphosphate is a ubiquitous second messenger
responsible for the release of Ca2+ from the ER, a tightly
controlled process which is critically important for maintaining
cellular functions, including cell growth, and neurite out-
growth (Berridge, 1993; Iketani et al., 2009). In this study, we
Figure 5 Effects of the IP3 receptor antagonists on the potentiation of NGF-induced neurite outgrowth by brexpiprazole. (A, B) The
potentiating effects of brexpiprazole (1.0 μM) on NGF-induced neurite outgrowth were antagonized by the selective IP3 receptor
antagonists, xestospongin C (1.0 μM) and 2-APB (100 μM). Neither, xestospongin C (1.0 μM) nor 2-APB (100 μM) alone altered NGF-
induced neurite outgrowth. Data show the mean7SEM (n=6). ***Po0.001 as compared with brexpiprazole group.
Figure 6 An increase in Hsp90α protein is required for
brexpiprazole-induced potentiation of NGF-induced neurite
outgrowth. Similar to aripiprazole (1.0 μM), brexpiprazole
(1.0 μM) signiﬁcantly increased Hsp90α protein in PC12 cells.
Data show the mean7SEM (n=8–18). **Po0.01, ***Po0.001 as
compared with the control (NGF (2.5 ng/ml) alone) group.
T. Ishima et al.510found that IP3 receptor antagonists, xestospongin C and 2-APB,
signiﬁcantly blocked potentiation of NGF-induced neurite out-
growth by brexpiprazole, highlighting the role of IP3 receptors
and intracellular Ca2+ signaling in this process. We already
know that several drugs utilize IP3 receptors to potentiate NGF-
induced neurite outgrowth (Nishimura et al., 2008; Ishima
et al., 2008, 2012; Minase et al., 2010; Hashimoto and
Ishima, 2010, 2011; Itoh et al., 2011; Ishima and Hashimoto,
2012). It is therefore reasonable to conclude that Ca2+ signaling
via IP3 receptors in the ER plays an important role in the
mechanism of action of brexpiprazole in its potentiation of
NGF-induced neurite outgrowth.
Considering the function of the aforementioned signaling
molecules in regulating protein synthesis-dependent learning
and memory (Costa-Mattioli et al., 2009), brexpiprazole
driven changes in these pathways may promote synthesis of
new proteins associated with neurite outgrowth. Hsp90 is an
essential molecular chaperone, ubiquitously active in many
signaling and cellular pathways (Mollapour and Neckers,
2012; Hartson and Matts, 2012; Makhnevych and Houry,2012). Current data suggest that Hsp90 participates in the
assembly of a number of protein complexes (Makhnevych and
Houry, 2012), including some required for antipsychotic drug
action. We found that the 5-HT1A receptor agonist, 8-OH-
DPAT also increased Hsp90α protein levels in PC12 cells,
although its effect was less pronounced than that of aripi-
prazole (Ishima et al., 2012). This places 5-HT1A receptor
activation within the cascade leading to increased Hsp90α
protein, although the precise mechanisms are unknown. It
would appear that brexpiprazole therapy increases Hsp90α
protein levels which potentiate NGF-induced neurite out-
growth again, by unknown mechanisms. Future studies need
to investigate whether serum levels of Hsp90α are altered in
patients with psychiatric disorders and explore whether
brexpiprazole may have any effect on those levels. It may
be that molecules which increase Hsp90α protein levels
confer a therapeutic advantage in psychiatric and neurode-
generative conditions by altering neurite outgrowth.
In conclusion, our results suggest that brexpiprazole potenti-
ates NGF-induced neurite outgrowth in PC12 cells, through
activation of 5-HT1A and 5-HT2A receptors and subsequent Ca
2+
signaling, via IP3 receptors. Furthermore, it is clear that the
increased levels of Hsp90α protein induced by brexpiprazole,
also play a role in NGF-induced neurite outgrowth.
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